Akamis Bio, a clinical-stage oncology company working to advance the standard of care in colorectal cancer, today announced early data from the on-going Phase 1b FORTRESS study of NG-350A, an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results